At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 91 enrolled
Drug / intervention
Jaktinib Hydrochloride Tablets +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 2 Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
In Brief
A Phase 2 clinical trial evaluating Jaktinib Hydrochloride Tablets and Placebo for Idiopathic Pulmonary Fibrosis. Completed, enrolled 91 participants across 1 site.
Detailed Summary
This is a multi-center, randomized, double-blinded, and placebo-controlled phase II study to evaluate the efficacy and safety of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartSep 2020
Primary CompletionJun 2022
TodayJul 2026
First PostedMar 18, 2020
Enrollment StartSep 8, 2020
Primary CompletionJun 9, 2022
TodayJul 1, 2026
Enrollment to primary: 1.8 yearsPosted 6.3 years ago
Interventions
Jaktinib Hydrochloride Tabletsdrug
Patients were administered Jaktinib taken orally as tablets twice daily
Jaktinib Hydrochloride Tabletsdrug
Patients were administered Jaktinib taken orally as tablets twice daily
Placebodrug
Patients were administered Placebo taken orally as tablets twice daily